Q: What is Truxima used for?

Truxima is used to treat: non-Hodgkin lymphoma chronic lymphocytic leukemia rheumatoid arthritis and others.

Q: How does Truxima work?

Targeting B-Cells Truxima belongs to a class of medications known as monoclonal antibodies. These are laboratory-made proteins designed to mimic the way the immune system attacks harmful cells. Truxima specifically targets a protein called CD20 , which is found on the surface of B-lymphocytes, also known as B-cells. Mechanism of Action When Truxima is infused into the body, it travels through the bloodstream and attaches itself to the CD20 protein on B-cells. Once it binds to these cells, it works in several ways to eliminate them: Immune System Activation: It signals other parts of the immune system to recognize and destroy the marked B-cells. Direct Cell Death: The binding process can trigger the B-cell to self-destruct. Cell Lysis: It can cause the cell membrane to break open, killing the cell. Impact on Different Conditions The way Truxima helps depends on the condition being treated: Cancers: In conditions like non-Hodgkin lymphoma and chronic lymphocytic leukemia, Truxima helps eliminate cancerous B-cells, which can slow or stop the progression of the disease. Autoimmune Disorders: In conditions like rheumatoid arthritis or vasculitis, the body's B-cells mistakenly attack healthy tissues. By reducing the number of these B-cells, Truxima helps decrease inflammation and prevent further damage to the body. Because Truxima targets both healthy and diseased B-cells, the body may be more susceptible to infections while the B-cell levels are low. Over time, the body usually produces new, healthy B-cells to replace those that were destroyed.

Q: What are the active ingredients in Truxima?

The active ingredient in Truxima is rituximab .

Q: What are the side effects of Truxima?

Common side effects of Truxima may include: infusion reactions fever chills and others Always consult with a healthcare professional about potential side effects.

Q: What drug class is Truxima?

Truxima belongs to the anti-CD20 monoclonal antibody drug class.

Q: What is the dosage of Truxima and how do I take it?

Administration Truxima is given as an infusion into a vein (intravenous infusion) by a healthcare provider. This procedure is performed in a medical setting, such as a hospital or infusion center, where you can be monitored for any reactions during the process. Treatment Schedule The timing and frequency of your infusions depend on the condition Truxima is being used to treat. Common patterns include: Weekly infusions: Some conditions require one infusion per week for a period of several weeks. Cyclical infusions: Other conditions may require two infusions given two weeks apart, with the cycle repeated every few months. Your doctor will determine the specific schedule that is right for you. Premedication To reduce the risk of infusion-related side effects, your healthcare provider will likely give you other medications before the Truxima infusion begins. These may include: Acetaminophen (to prevent fever) An antihistamine (to prevent allergic reactions) A corticosteroid (to reduce inflammation) Missed Doses If you miss an appointment for a Truxima infusion, contact your doctor or the infusion clinic immediately to reschedule. It is important to receive your doses as scheduled to achieve the best results from the treatment.

Q: Is Truxima safe during pregnancy and breastfeeding?

Pregnancy Truxima can cause harm to a fetus. Research indicates that rituximab products can cross the placenta and may cause a decrease in B-cells in the unborn baby. It is important to inform your doctor if you are pregnant or planning to become pregnant before starting this medication. Individuals who can become pregnant should use effective birth control during treatment and for 12 months after the final dose of Truxima to prevent pregnancy. Breastfeeding It is not known if Truxima is present in human breast milk. Because of the risk of serious adverse reactions in a nursing child, it is typically recommended to avoid breastfeeding during treatment and for at least 6 months after the last dose. Consult with a healthcare professional to determine the safest options for your situation.

Q: What forms and strengths does Truxima come in?

Available Forms Truxima is supplied as a sterile, preservative-free solution in vials. It is intended for intravenous use only and is provided as a clear to opalescent, colorless to pale yellow liquid. Administration This medication is administered as an intravenous infusion into a vein by a healthcare provider in a clinical setting. Before administration, the concentrated solution from the vial is diluted into an infusion bag containing a compatible fluid.

Q: What is the FDA approval status of Truxima?

FDA Approval and Biosimilar Status The U.S. Food and Drug Administration (FDA) approved Truxima (rituximab-abbs) in November 2018. It is the first biosimilar to Rituxan (rituximab) to be approved in the United States. A biosimilar is a biological product that is highly similar to an already approved biological medicine, with no clinically meaningful differences in terms of safety, purity, and potency. Approved Indications Truxima is indicated for the treatment of several conditions in adult patients, including: Relapsed or refractory, low-grade or follicular, B-cell Non-Hodgkin’s Lymphoma (NHL). Previously untreated follicular B-cell NHL. Non-progressing, low-grade, B-cell NHL. Previously untreated diffuse large B-cell NHL. Chronic Lymphocytic Leukemia (CLL). Rheumatoid Arthritis (RA) in combination with methotrexate. Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA). Boxed Warnings Truxima carries a Boxed Warning, the FDA’s most serious warning, for the following risks: Infusion Reactions: Severe and fatal infusion-related reactions can occur. Most fatal reactions happen during the first infusion. Severe Mucocutaneous Reactions: Potentially fatal skin and mouth reactions, such as Stevens-Johnson syndrome, have occurred. Hepatitis B Virus (HBV) Reactivation: HBV reactivation can lead to serious liver problems, including liver failure and death. Screening for HBV is required before starting treatment. Progressive Multifocal Leukoencephalopathy (PML): This is a rare, serious brain infection caused by the JC virus that can lead to severe disability or death.

Question 1

What is Truxima?

Accepted Answer

Truxima is a biological medication known as a monoclonal antibody. It is designed to recognize and attach to a specific protein called CD20, which is found on the surface of B-cells, a type of white blood cell.

Once attached, the medication helps the body's immune system identify and eliminate these cells or helps regulate their activity. As a biosimilar, it is highly similar to its reference product and provides the same therapeutic effects.

Question 2

What is Truxima used for?

Accepted Answer

Truxima is used to treat:

non-Hodgkin lymphoma
chronic lymphocytic leukemia
rheumatoid arthritis
and others.

Question 3

How does Truxima work?

Accepted Answer

Targeting B-Cells

Truxima belongs to a class of medications known as monoclonal antibodies. These are laboratory-made proteins designed to mimic the way the immune system attacks harmful cells. Truxima specifically targets a protein called CD20, which is found on the surface of B-lymphocytes, also known as B-cells.

Mechanism of Action

When Truxima is infused into the body, it travels through the bloodstream and attaches itself to the CD20 protein on B-cells. Once it binds to these cells, it works in several ways to eliminate them:

Immune System Activation: It signals other parts of the immune system to recognize and destroy the marked B-cells.
Direct Cell Death: The binding process can trigger the B-cell to self-destruct.
Cell Lysis: It can cause the cell membrane to break open, killing the cell.

Impact on Different Conditions

The way Truxima helps depends on the condition being treated:

Cancers: In conditions like non-Hodgkin lymphoma and chronic lymphocytic leukemia, Truxima helps eliminate cancerous B-cells, which can slow or stop the progression of the disease.
Autoimmune Disorders: In conditions like rheumatoid arthritis or vasculitis, the body's B-cells mistakenly attack healthy tissues. By reducing the number of these B-cells, Truxima helps decrease inflammation and prevent further damage to the body.

Because Truxima targets both healthy and diseased B-cells, the body may be more susceptible to infections while the B-cell levels are low. Over time, the body usually produces new, healthy B-cells to replace those that were destroyed.

Question 4

What are the active ingredients in Truxima?

Accepted Answer

The active ingredient in Truxima is rituximab.

Question 5

What are the side effects of Truxima?

Accepted Answer

Common side effects of Truxima may include:

infusion reactions
fever
chills
and others

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Truxima?

Accepted Answer

Truxima belongs to the anti-CD20 monoclonal antibody drug class.

Question 7

What is the dosage of Truxima and how do I take it?

Accepted Answer

Administration

Truxima is given as an infusion into a vein (intravenous infusion) by a healthcare provider. This procedure is performed in a medical setting, such as a hospital or infusion center, where you can be monitored for any reactions during the process.

Treatment Schedule

The timing and frequency of your infusions depend on the condition Truxima is being used to treat. Common patterns include:

Weekly infusions: Some conditions require one infusion per week for a period of several weeks.
Cyclical infusions: Other conditions may require two infusions given two weeks apart, with the cycle repeated every few months.

Your doctor will determine the specific schedule that is right for you.

Premedication

To reduce the risk of infusion-related side effects, your healthcare provider will likely give you other medications before the Truxima infusion begins. These may include:

Acetaminophen (to prevent fever)
An antihistamine (to prevent allergic reactions)
A corticosteroid (to reduce inflammation)

Missed Doses

If you miss an appointment for a Truxima infusion, contact your doctor or the infusion clinic immediately to reschedule. It is important to receive your doses as scheduled to achieve the best results from the treatment.

Question 8

Is Truxima safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Truxima can cause harm to a fetus. Research indicates that rituximab products can cross the placenta and may cause a decrease in B-cells in the unborn baby. It is important to inform your doctor if you are pregnant or planning to become pregnant before starting this medication.

Individuals who can become pregnant should use effective birth control during treatment and for 12 months after the final dose of Truxima to prevent pregnancy.

Breastfeeding

It is not known if Truxima is present in human breast milk. Because of the risk of serious adverse reactions in a nursing child, it is typically recommended to avoid breastfeeding during treatment and for at least 6 months after the last dose. Consult with a healthcare professional to determine the safest options for your situation.

Question 9

What forms and strengths does Truxima come in?

Accepted Answer

Available Forms

Truxima is supplied as a sterile, preservative-free solution in vials. It is intended for intravenous use only and is provided as a clear to opalescent, colorless to pale yellow liquid.

Administration

This medication is administered as an intravenous infusion into a vein by a healthcare provider in a clinical setting. Before administration, the concentrated solution from the vial is diluted into an infusion bag containing a compatible fluid.

Question 10

What is the FDA approval status of Truxima?

Accepted Answer

FDA Approval and Biosimilar Status

The U.S. Food and Drug Administration (FDA) approved Truxima (rituximab-abbs) in November 2018. It is the first biosimilar to Rituxan (rituximab) to be approved in the United States. A biosimilar is a biological product that is highly similar to an already approved biological medicine, with no clinically meaningful differences in terms of safety, purity, and potency.

Approved Indications

Truxima is indicated for the treatment of several conditions in adult patients, including:

Relapsed or refractory, low-grade or follicular, B-cell Non-Hodgkin’s Lymphoma (NHL).
Previously untreated follicular B-cell NHL.
Non-progressing, low-grade, B-cell NHL.
Previously untreated diffuse large B-cell NHL.
Chronic Lymphocytic Leukemia (CLL).
Rheumatoid Arthritis (RA) in combination with methotrexate.
Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA).

Boxed Warnings

Truxima carries a Boxed Warning, the FDA’s most serious warning, for the following risks:

Infusion Reactions: Severe and fatal infusion-related reactions can occur. Most fatal reactions happen during the first infusion.
Severe Mucocutaneous Reactions: Potentially fatal skin and mouth reactions, such as Stevens-Johnson syndrome, have occurred.
Hepatitis B Virus (HBV) Reactivation: HBV reactivation can lead to serious liver problems, including liver failure and death. Screening for HBV is required before starting treatment.
Progressive Multifocal Leukoencephalopathy (PML): This is a rare, serious brain infection caused by the JC virus that can lead to severe disability or death.

Question 11

What should I know about Truxima and cost?

Accepted Answer

Factors Influencing Cost

The price of Truxima can vary significantly depending on several factors, including:

The specific condition being treated and the required dosage.
The frequency of the infusion sessions.
Your health insurance plan, including deductibles and co-pays.
The setting where you receive the infusion, such as a hospital outpatient department or a private clinic.

Biosimilar Savings

As a biosimilar to Rituxan, Truxima is designed to provide a more cost-effective treatment option. Biosimilars are highly similar to the original biologic drug but are often available at a lower list price than the reference product.

Financial Assistance

Financial support may be available for patients who meet certain eligibility criteria. This can include:

Co-pay assistance: Programs that help reduce out-of-pocket costs for patients with commercial insurance.
Patient assistance programs: Support for individuals who are uninsured or underinsured.

Because Truxima must be administered by a healthcare professional through an intravenous infusion, the total cost will also include fees for the medical staff and the facility where the procedure takes place. It is recommended to check with your insurance provider regarding prior authorization requirements before starting treatment.

Truxima

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Truxima

Hospitals.net Disclosure